Government-funded trial will test psilocybin as treatment for opioid use disorder
Pharmaceutical journal/The pharmaceutical journal 2024 DOI: 10.1211/pj.2024.1.335169 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Trial Peer reviewed |
|---|---|
| Sample size | 28 |
| Population | People recovering from opioid addiction who have recently undergone detoxification from street opioids |
| Intervention | Psilocybin therapy |
| Topics | Addiction Psilocybin |
| Key findings | The trial will investigate whether psilocybin therapy can help prevent relapse in people recovering from opioid addiction. |
Abstract
A “UK first” trial will investigate whether psilocybin — the active ingredient in ‘magic mushrooms’ — can help prevent relapse in people recovering from opioid addiction. The psilocybin study, led by researchers at Imperial College London, will involve 28 participants who have recently undergone detoxification from ‘street’ opioids. Participants will receive psilocybin therapy at the […]
Comparable studies
Other non-randomized and open-label trials on psilocybin for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction Smokers | 2015 | Open-label pilot study | n = 15 |
| The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions Participants in a psilocybin-assisted treatment study for alcohol dependence | 2018 | Open-label pilot (proof-of-concept) study with qualitative content analysis | n = 17 |
| It’s time to take psilocybin seriously as a possible treatment for substance use disorders | 2016 | Pilot study | |
| Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study Treatment-seeking adults with severe alcohol use disorder | 2025 | Open-label, single-group study | n = 10 |